Join Growin Stock Community!

Nanoviricides, inc.NNVC.US Overview

US StockHealthcare
(No presentation for NNVC)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NNVC AI Insights

NNVC Overall Performance

NNVC AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NNVC Recent Performance

-7.61%

Nanoviricides, inc.

0.05%

Avg of Sector

-0.31%

S&P500

NNVC PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NNVC Key Information

NNVC Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NNVC Profile

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Price of NNVC

NNVC FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NNVC Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.16
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.16
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NNVC's latest earnings report released?

    The most recent financial report for Nanoviricides, inc. (NNVC) covers the period of 2026Q2 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NNVC's short-term business performance and financial health. For the latest updates on NNVC's earnings releases, visit this page regularly.

  • How much cash does NNVC have?

    At the end of the period, Nanoviricides, inc. (NNVC) held Total Cash and Cash Equivalents of 5.15M, accounting for 0.42 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NNVC's EPS continuing to grow?

    According to the past four quarterly reports, Nanoviricides, inc. (NNVC)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NNVC?

    Nanoviricides, inc. (NNVC)'s Free Cash Flow (FCF) for the period is -2.05M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.